Stability and degradation profiles of Spantide II in aqueous solutions

European Journal of Pharmaceutical Sciences

Volumn 27, Issue 2-3, 2006, Pages 158-166

  Kikwai, Loice ^a   Babu, R Jayachandra ^a   Kanikkannan, Narayanasamy ^a   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Peptide; Spantide II; Stability; Topical; Transdermal

Indexed keywords

2 PYRROLIDINONE; ALDEHYDE DERIVATIVE; HYDROGEN PEROXIDE; OXIDIZING AGENT; PEPTIDE FRAGMENT; PHENYLALANINE DERIVATIVE; PIPERAZINE DERIVATIVE; SPANTIDE; SPANTIDE II; UNCLASSIFIED DRUG;

ACIDITY; ALKALINITY; AQUEOUS SOLUTION; ARTICLE; CHEMICAL BOND; DRUG DEGRADATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SCREENING; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PH; PRIORITY JOURNAL; RACEMIZATION; SHELF LIFE; TEMPERATURE; THERMOSTABILITY;

ANTI-INFLAMMATORY AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; ETHANOL; HYDROGEN PEROXIDE; HYDROGEN-ION CONCENTRATION; OXIDANTS; SOLUTIONS; SOLVENTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTANCE P; TEMPERATURE; WATER;

EID: 29244466827     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2005.09.005     Document Type: Article

References (22)

1. R.J. Babu, L. Kikwai, L.T. Jaiani, N. Kanikkannan, C.A. Armstrong, J.C. Ansel, and M. Singh Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: Spantide II Pharm. Res. 21 2004 108 113
2. J.R. Brown, P. Perry, S. Hefeneider, and A.C. Ansel Neuropeptide modulation of keratinocyte cytokine production P. Oppenheim D. Kluger Molecular and Cellular Biology of Cytokines 1990 Wiley-Liss Inc. New York 451 456
3. J. Csapá, Z. Csapó-Kiss, L. Wágner, T. Tálos, T.G. Martin, S. Folestad, A. Tivesten, and S. Némethy Hydrolysis of proteins performed at high temperatures and for short times with reduced racemization, in order to determine the enantiomers of d- and l-amino acids Anal. Chim. Acta 339 1997 99 107
4. N.N. Epstein, W.L. Epstein, and J.H. Epstein Atrophic striae in patients with inguinal intertrigo Arch. Dermatol. 87 1963 450 457
5. J. Fransson, E. Florin-Robertsson, K. Axelsson, and C. Nyhle'n Oxidation of human insulin-like growth factor I in formulation studies: kinetics of methionine oxidation in aqueous solution and in solid state Pharm. Res. 13 1996 1252 1257
6. C. Goolcharran, and R.T. Borchardt Kinetics of diketopiperazine formation using model peptides J. Pharm. Sci. 87 1998 283 288
7. C. Goolcharran, J.L. Cleland, R. Keck, A.J. Jones, and R.T. Borchardt Comparison of the rates of deamidation, diketopiperazine formation and oxidation in recombinant human vascular endothelial growth factor and model peptides AAPS PharmSci. 2 2000 E5
8. L.T. Jaiani, M. Sachdeva, B.R. Jaychandra, N. Kanikkannan, F.J. Legat, N.G. Neparidze, L. Kikwai, C.A. Armstrong, and J.C. Ansel Inhibition of allergic contact dermatitis by a topically applied SP receptor antagonist Invest. Dermatol. 119 2002 Abstract 655
9. P. Kaushal, I. Burducea, S. Hunt, A. Geblaoui, R. Gentz, and F. Khan Identification of chemical modifications in proteins, myeloid progenitor inhibitory factor-1 (MPIF-1) and keratinocyte growth factor-2 (KGF-2) by matrix-assisted laser desorption mass spectrometry Pharm. Sci. 1 1998 S537
10. L. Kikwai, R.J. Babu, N. Kanikkannan, and M. Singh Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis J. Pharm. Pharmacol. 56 2004 19 25
11. A. Ljungqvist, J.Y. Chu, P.F. Tang, W. Bender, R. Hakanson, S. Leander, S. Rosell, and K. Folkers Increased potency of antagonists of substance P having asparagine in position 6 Regul. Pept. 24 1989 283 291
12. M.C. Manning, K. Patel, and R.T. Borchardt Stabil. Protein Pharmaceut. Pharmacol. Res. 6 1989 903 918
13. C. Oliyai, and R.T. Borchardt Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide Pharm. Res. 10 1993 95 102
14. C. Oliyai, C. Schoneich, G.S. Wilson, and R.T. Borchardt Topics in pharmaceutical sciences D.J.A. Crommelin K.K. Mihda Medpharm 1992 Scientific Stuttgart 23 46
15. 8] substance P{6-11} J. Pharm. Biomed. Anal. 19 1999 277 284
16. 8]-substance P{6-11} in aqueous solution Anal. Biochem. 227 1995 334 341
17. J.L.E. Reubsaet, J.H. Beijnen, A. Bult, R.J. van Maanen, J.A.D. Marchal, and W.J.M.J. Underberg Analytical techniques used to study the degradation of proteins and peptides: chemical instability Pharm. Biomed. Anal. 17 1998 955 978
18. T. Scholzen, C.A. Armstrong, N.W. Bunnett, T.A. Luger, J.E. Olerud, and J.C. Ansel Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems Exp. Derm. 7 1998 81 96
19. K. Takeda, S. Arase, and S. Takahashi Side effects of topical corticosteroids and their prevention Drugs 36 1988 15 23
20. The United States Pharmacopoeia 28, The National Formulary 23, United States Pharmacopoeial Convention, Rockville, MD, 2004.
21. W. Wang Instability, stabilization, and formulation of liquid protein pharmaceuticals Int. J. Pharm. 185 1999 129 188
22. J.C. Waterval, J.C. Bloks, R.W. Sparidans, J.H. Beijnen, I.M. Rodriguez-Campos, A. Bult, H. Lingeman, and W.J. Underberg Degradation kinetics of aplidine, a new marine anti-tumoural cyclic peptide, in aqueous solution J. Chromatogr. B Biomed. Sci. 754 2001 161 168